![Christian Bailey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christian Bailey
Private Equity Investor chez UP Partners Management Co. LLC
Postes actifs de Christian Bailey
Sociétés | Poste | Début | Fin |
---|---|---|---|
UP Partners Management Co. LLC
![]() UP Partners Management Co. LLC Investment ManagersFinance UP Partners Management Co. LLC (UP Partners) is a venture capital firm founded in 2019 by Cyrus Sigari and Ben Marcus. The firm is headquartered in Santa Monica, California. | Private Equity Investor | 01/07/2020 | - |
Historique de carrière de Christian Bailey
Anciens postes connus de Christian Bailey
Sociétés | Poste | Début | Fin |
---|---|---|---|
Ligon Discovery, Inc.
![]() Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Directeur Général | 01/06/2010 | 01/12/2011 |
Fondateur | 01/06/2010 | 01/12/2011 | |
Lincoln Asset Management Group LLC
![]() Lincoln Asset Management Group LLC Investment ManagersFinance Founded by Christian Bailey, Lincoln Asset Management Group LLC is a hedge fund manager located in New York City. They manage the Lincoln Vector Fund LP and the Lincoln Futures Fund. | Directeur en chef des Investissements | - | - |
Gestionnaire de Portefeuille-Actions | - | - | |
President | - | - | |
incTANK Inc
![]() incTANK Inc Investment ManagersFinance incTANK Inc (incTANK) is a venture capital firm founded in 1999 by Karl H. Ruping. The firm is headquartered in the Cambridge, Massachusetts. | Private Equity Investor | 08/12/2010 | - |
Formation de Christian Bailey
University of Oxford | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Royaume-Uni | 2 |
Opérationnelle
Private Equity Investor | 2 |
Chief Investment Officer | 1 |
Portfolio Manager-Equities | 1 |
Sectorielle
Finance | 4 |
Consumer Services | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 4 |
---|---|
Lincoln Asset Management Group LLC
![]() Lincoln Asset Management Group LLC Investment ManagersFinance Founded by Christian Bailey, Lincoln Asset Management Group LLC is a hedge fund manager located in New York City. They manage the Lincoln Vector Fund LP and the Lincoln Futures Fund. | Finance |
incTANK Inc
![]() incTANK Inc Investment ManagersFinance incTANK Inc (incTANK) is a venture capital firm founded in 1999 by Karl H. Ruping. The firm is headquartered in the Cambridge, Massachusetts. | Finance |
UP Partners Management Co. LLC
![]() UP Partners Management Co. LLC Investment ManagersFinance UP Partners Management Co. LLC (UP Partners) is a venture capital firm founded in 2019 by Cyrus Sigari and Ben Marcus. The firm is headquartered in Santa Monica, California. | Finance |
Ligon Discovery, Inc.
![]() Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Commercial Services |
- Bourse
- Insiders
- Christian Bailey
- Expérience